Greenberg Traurig, LLP announced that six of its Intellectual Property & Technology attorneys from the firm’s Boston office have been recognized in the 2026 edition of the Intellectual Asset Management (IAM) Strategy 300 – The World's Leading IP Strategists. The IAM Strategy 300 is a respected guide that identifies individuals who are at the forefront of crafting and implementing strategies to optimize the value of intellectual property portfolios worldwide.
The IAM Strategy 300 features professionals from a diverse range of organizations, including service providers, corporations, research institutions, and universities. Selection is based on confidential online nominations and extensive research involving interviews and correspondence with senior members of the global IP community. Dykeman, co-chair of Greenberg Traurig’s global Life Sciences & Medical Technology Group and a registered patent attorney with over 25 years of experience, focuses his practice on securing worldwide IP protection and business strategies for high-tech clients.
His expertise spans life sciences, medical devices, robotics, materials science, and information technology. Roman Fayerberg, also a registered patent attorney, brings broad experience in helping clients strategically protect and leverage innovations on a global scale. He advises on worldwide patent portfolio development, freedom-to-operate analyses, patent landscape assessments, infringement and validity issues, and conducts due diligence for venture capital investments, mergers and acquisitions, and licensing.
, has designed and implemented IP strategies for companies at all stages, from startups to publicly traded entities. He has secured thousands of patents and developed complex portfolios that have facilitated significant partnerships, particularly in the life sciences sector. , specializes in aligning life sciences clients’ IP strategies with their business objectives.
His work includes patent preparation and prosecution, portfolio management, freedom-to-operate analyses, invalidity and non-infringement opinions, due diligence, and coordinating IP with clinical strategies. His technical expertise covers biochemistry, bioenergy, cell signaling, diagnostics, genetics, immunology, microbiome research, nanoparticle carriers, nucleic acids, synthetic biology, and therapeutics. Pham, co-chair of the Venture Capital & Emerging Technology Practice, focuses on creating, implementing, and protecting IP rights for technology and life sciences clients ranging from venture-backed startups to multinational corporations.
He also mentors entrepreneurs and early-stage ventures, helping them leverage innovations for strategic commercial opportunities. ) Tibbetts provides business-oriented IP legal counseling for software, artificial intelligence, and electronics technologies. His strategic approach integrates open-source practices and trade secret policies alongside patents.
Tibbetts advises on licensing, enforcement, diligence, and defense against infringement claims. His patents have supported clients in securing funding rounds, survived Patent Trial and Appeal Board invalidity challenges, and been enforced against competitors. Supreme Court and Federal Circuit regarding software patentability.
“This recognition reflects the exceptional depth and breadth of our IP team,” said Greenberg Traurig Boston office Co-Managing Shareholders David J. Dykeman and Terence P. McCourt in a joint statement.
Six Greenberg Traurig IP Attorneys Earn Spot in 2026 IAM Strategy 300 for Leading IP Strategy Expertise Six attorneys from Greenberg Traurig’s Boston office have been named to the prestigious 2026 IAM Strategy 300 list, highlighting their leadership in developing and executing intellectual property strategies that maximiz... Read the full IIPLA article: https://iipla.org/news/six-greenberg-traurig-ip-attorneys-earn-spot-in-2026-iam-strategy-300-for-leading-ip-strategy-expertise